DK1068238T3 - Integrinheterodimer og subunit deraf - Google Patents
Integrinheterodimer og subunit derafInfo
- Publication number
- DK1068238T3 DK1068238T3 DK99919725.4T DK99919725T DK1068238T3 DK 1068238 T3 DK1068238 T3 DK 1068238T3 DK 99919725 T DK99919725 T DK 99919725T DK 1068238 T3 DK1068238 T3 DK 1068238T3
- Authority
- DK
- Denmark
- Prior art keywords
- rodimes
- subunit
- integrity unit
- integrity
- unit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9801164A SE9801164D0 (sv) | 1998-04-02 | 1998-04-02 | Integrin subinit alfa10 |
SE9900319A SE9900319D0 (sv) | 1999-01-28 | 1999-01-28 | The integrin subunit alfa10, an antiadhesive target |
PCT/SE1999/000544 WO1999051639A1 (en) | 1998-04-02 | 1999-03-31 | An integrin heterodimer and a subunit thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1068238T3 true DK1068238T3 (da) | 2013-01-14 |
Family
ID=26663256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99919725.4T DK1068238T3 (da) | 1998-04-02 | 1999-03-31 | Integrinheterodimer og subunit deraf |
Country Status (8)
Country | Link |
---|---|
US (5) | US7029858B1 (da) |
EP (1) | EP1068238B1 (da) |
JP (3) | JP4912528B2 (da) |
AU (1) | AU761430B2 (da) |
CA (1) | CA2324381C (da) |
DK (1) | DK1068238T3 (da) |
ES (1) | ES2396693T3 (da) |
WO (1) | WO1999051639A1 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029858B1 (en) | 1998-04-02 | 2006-04-18 | Cartela Ab | Integrin heterodimer and a subunit thereof |
US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
SE9902056D0 (sv) * | 1999-06-03 | 1999-06-03 | Active Biotech Ab | An integrin heterodimer and an alpha subunit thereof |
JP4399533B2 (ja) * | 2002-06-14 | 2010-01-20 | キシンテラ、アクチボラグ | 幹細胞のマーカーおよびその使用 |
ATE412420T1 (de) * | 2002-06-17 | 2008-11-15 | Cartela R & D Ab | Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro |
SE0301087D0 (sv) | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
WO2004089990A1 (en) * | 2003-04-14 | 2004-10-21 | Cartela Ab | New monoclonal antibody capable of binding integrin alpha 10 beta 1 |
WO2005118809A2 (en) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
WO2008068481A1 (en) * | 2006-12-05 | 2008-06-12 | Cartela R & D Ab | New compounds, methods and uses |
WO2008072000A2 (en) * | 2006-12-15 | 2008-06-19 | Xintela Ab (Se) | Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover |
DK3258964T3 (da) | 2015-02-16 | 2021-02-08 | Xintela Ab | Detektion og behandling af maligne tumorer i CNS |
CN108341853B (zh) * | 2017-01-22 | 2022-06-21 | 中国科学院化学研究所 | 人血清白蛋白特异性识别多肽及其应用 |
BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
BR112019024558A2 (pt) * | 2017-06-29 | 2020-06-09 | Xintela Ab | composição, métodos para determinar a qualidade de uma composição, para isolar e para produzir uma população de condrócitos de alta qualidade, para otimizar a potência condrocítica de uma composição, para aumentar a taxa de proliferação de condrócitos, e, uso do método. |
BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
JP2022530339A (ja) | 2019-04-15 | 2022-06-29 | タルギンタ エービー | インテグリンα10および侵攻性癌型 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
US5310874A (en) * | 1991-05-03 | 1994-05-10 | The Scripps Research Institute | Integrin α subunit cytoplasmic domain polypeptides and antibodies |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
AU3972793A (en) * | 1992-04-10 | 1993-11-18 | General Hospital Corporation, The | Cartilage matrix protein and methods for use |
AU6639394A (en) * | 1993-04-26 | 1994-11-21 | Children's Medical Center Corporation | A method for rapid formation and isolation of focal adhesion complexes |
US5853987A (en) * | 1995-04-24 | 1998-12-29 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
WO1997031653A1 (en) | 1996-03-01 | 1997-09-04 | Beth Israel Deaconess Medical Center | Diagnosis and treatment of metastic breast carcinoma |
US5843436A (en) | 1996-04-22 | 1998-12-01 | The Trustees Of Columbia University, In The City Of New York | Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci |
US6046316A (en) * | 1997-12-09 | 2000-04-04 | Wayne State University | Nucleic acid encoding truncated integrins |
US7029858B1 (en) * | 1998-04-02 | 2006-04-18 | Cartela Ab | Integrin heterodimer and a subunit thereof |
JP2001354699A (ja) | 2000-06-12 | 2001-12-25 | Teijin Ltd | アンギオテンシンiiと結合する抗体 |
US7153944B2 (en) | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
CA2480326A1 (en) * | 2002-04-12 | 2003-12-11 | Cartela Ab | Knockout mice and their use |
JP4399533B2 (ja) * | 2002-06-14 | 2010-01-20 | キシンテラ、アクチボラグ | 幹細胞のマーカーおよびその使用 |
WO2004089990A1 (en) * | 2003-04-14 | 2004-10-21 | Cartela Ab | New monoclonal antibody capable of binding integrin alpha 10 beta 1 |
SE0301087D0 (sv) * | 2003-04-14 | 2003-04-14 | Cartela Ab | New monoclonal antibody |
-
1999
- 1999-03-31 US US09/647,544 patent/US7029858B1/en not_active Expired - Lifetime
- 1999-03-31 ES ES99919725T patent/ES2396693T3/es not_active Expired - Lifetime
- 1999-03-31 JP JP2000542360A patent/JP4912528B2/ja not_active Expired - Fee Related
- 1999-03-31 CA CA2324381A patent/CA2324381C/en not_active Expired - Lifetime
- 1999-03-31 DK DK99919725.4T patent/DK1068238T3/da active
- 1999-03-31 EP EP99919725A patent/EP1068238B1/en not_active Expired - Lifetime
- 1999-03-31 AU AU37380/99A patent/AU761430B2/en not_active Expired
- 1999-03-31 WO PCT/SE1999/000544 patent/WO1999051639A1/en active IP Right Grant
-
2006
- 2006-02-06 US US11/347,179 patent/US8048991B2/en not_active Expired - Fee Related
-
2011
- 2011-03-30 JP JP2011076144A patent/JP5650038B2/ja not_active Expired - Lifetime
- 2011-09-06 US US13/226,323 patent/US20120136141A1/en not_active Abandoned
-
2012
- 2012-10-15 US US13/651,602 patent/US8895253B2/en not_active Expired - Fee Related
-
2014
- 2014-06-27 JP JP2014132644A patent/JP2014221055A/ja active Pending
- 2014-11-24 US US14/552,308 patent/US10081666B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4912528B2 (ja) | 2012-04-11 |
JP2014221055A (ja) | 2014-11-27 |
JP2002517182A (ja) | 2002-06-18 |
US20060178503A1 (en) | 2006-08-10 |
CA2324381A1 (en) | 1999-10-14 |
US10081666B2 (en) | 2018-09-25 |
EP1068238B1 (en) | 2012-10-03 |
CA2324381C (en) | 2013-02-26 |
AU3738099A (en) | 1999-10-25 |
US20130137118A1 (en) | 2013-05-30 |
JP5650038B2 (ja) | 2015-01-07 |
JP2011217745A (ja) | 2011-11-04 |
AU761430B2 (en) | 2003-06-05 |
US8895253B2 (en) | 2014-11-25 |
US20170121386A1 (en) | 2017-05-04 |
US20120136141A1 (en) | 2012-05-31 |
US8048991B2 (en) | 2011-11-01 |
WO1999051639A1 (en) | 1999-10-14 |
EP1068238A1 (en) | 2001-01-17 |
US20180079795A9 (en) | 2018-03-22 |
US7029858B1 (en) | 2006-04-18 |
ES2396693T3 (es) | 2013-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1454907T3 (da) | Quninazolin og pyridopyrmidin-derivativer | |
NO20032753D0 (no) | Forbindelse og anvendelse derav | |
IS6411A (is) | Kaspasa tálmar og notkun þeirra | |
IS6385A (is) | Ný notkun og nýjar N-asabísýkló-amíð afleiður | |
IS5525A (is) | Innúðabúnaður og aðferð | |
DK0815861T3 (da) | Sulfonamider og anvendelse deraf | |
NO20001323D0 (no) | Dipeptid-apoptose inhibitorer og deres anvendelse | |
NO20021449D0 (no) | Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav | |
IS4481A (is) | Díhýdrópyramídín og notkun þeirra | |
NO20014560D0 (no) | Quinasoliner og terapautisk anvendelse derav | |
NO20006488D0 (no) | Sammensetning og anvendelse | |
NO20010442D0 (no) | Lysledende anordning og fremgangsmåte | |
DK1068238T3 (da) | Integrinheterodimer og subunit deraf | |
NO20004274D0 (no) | Proteaseaktivert reseptor 4 og anvendelse derav | |
NO20003916D0 (no) | Benzotiadiazoler og derivater | |
NO20005502D0 (no) | Polymerer og deres anvendelse | |
NO995811L (no) | Selvgjenopprettende og selvbekreftende kryptosystemer | |
DK1140952T3 (da) | Phosphororganiske forbindelser og anvendelse heraf | |
NO984921D0 (no) | Tienopyridinderivater og deres anvendelse | |
DE60041297D1 (de) | Empfangsgerät und- Verfahren | |
NO983159L (no) | Koblingsanordning og koblingsbeslag | |
NO20000493D0 (no) | Sveisemateriale og anvendelse derav | |
DK0936968T3 (da) | Forbindelsesindretning og forbindelsesfremgangsmåde | |
DE59812220D1 (de) | Halte- und trageband | |
NO306663B1 (no) | Opplagringsanordning og lagerenhet |